Naslov
What’s new in neoadjuvant treatment of breast cancer?

Autori
Silovski, Tajana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Libri Oncologici / - , 2017, 3-3

Skup
9th Symposium and Annual Meeting of Croatian Society for Medical Oncology of Croatian Medical Association with International Participation 11th Meeting of Oncology Pharmacy Section of Croatian Pharmaceutical Society with International Participation Croatian Society for Medical Oncology, Croatian Medical Association Oncology Pharmacy Session, Croatian Pharmaceutical Society

Mjesto i datum
Varaždin, Hrvatska, 20.10.2017. - 21.10.2017

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Breast cancer, neoadjuvant treatment

Sažetak
Neoadjuvant approach provides many benefi ts for patients with early breast cancer. Indication has to be provided by multidisciplinary team. Patients, candidates for neoadjuvant treatment and therapy regimens, have to be carefully selected. Therapy response has to be closely monitored. Surgery timing and radiotherapy extent have to be disscussed by the team. In neoadjuvant treatment of early HER2 positive breast cancer, ER positive status is associated with lower response. Adding antihormonal therapy does not improve pCR, although it does not antagonize chemo- or targeted therapy efficiency.Immune system is crucial for anti-cancer therapy. Tumor infi ltrating lymphocytes (TILs) are associated with high pCR rates and may correlate with more aggressive behaviour. TILs can be induces what can imply relevant immunotherapy based regimens. Many ongoing clinical trials are currently using immunotherapy combination.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA